Previous 10 | Next 10 |
home / stock / lzagy / lzagy news
2023-07-21 13:10:24 ET Lonza Group AG (LZAGY) Q2 2023 Earnings Conference Call July 21, 2023, 08:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosser - JPMorgan James Quigley - Mor...
2023-07-16 20:14:12 ET UK-based HSBC initiated coverage of 19 major biopharma stocks this past week, labeling Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) and Lonza ( OTCPK:LZAGY ) ( OTCPK:LZAGF ) as potential comeback stories, wh...
2023-06-30 03:41:20 ET Summary Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's capital allocation priorities. In addition, the compa...
2023-05-10 15:30:04 ET Lonza Group AG (LZAGY) Q1 2023 Earnings Conference Call May 09, 2023, 09:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Matthew Weston - Credit Suisse Vineet Agrawal ...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
Summary With the JPM healthcare conference (in line with the CEO indication) and the latest results, we decide to lower our 2023 EBITDA assumption. Despite that, Lonza is still attractive on an EV/EBITDA basis. Higher dividend per share and solid balance sheet. Our buy rating is sti...
Lonza Group AG (LZAGY) Q4 2022 Earnings Conference Call January 25, 2023, 08:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosser - JPMorgan Vineet Agrawal - Citi James Quigley - Mor...
The following slide deck was published by Lonza Group AG in conjunction with their 2022 Q4 earnings call. For further details see: Lonza Group AG 2022 Q4 - Results - Earnings Call Presentation
Lonza Group AG press release ( OTCPK:LZAGY ): FY Non-GAAP EPS of CHF 14.71. Revenue of CHF6.22B (+15.2% Y/Y). Lonza provides the following Outlook for Full-Year 2023: High single-digit CER sales growth; CORE EBITDA Margin of 30–31%. Lonza confirms its Mid-Term Guid...
Summary No disclosure in Q3, but positive news ahead. Capacity constraint will positively impact Lonza's earnings. The CMDO industry almost totally offset raw material inflationary pressure, we reiterate our positive key takeaways, confirming our buy rating target. ...
News, Short Squeeze, Breakout and More Instantly...
Lonza Group AG ADR Company Name:
LZAGY Stock Symbol:
OTCMKTS Market:
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...
FFW Corp. (FFWC) is expected to report for Q2 2024 ResMed Inc. (RMD) is expected to report $1.81 for Q2 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2023-12-31 ChoiceOne Financial Services Inc. (COFS) is expected to report $0.64 for Q4 2023 First ...
Lonza Group AG ADR (LZAGY) is expected to report for Q4 2023